4//SEC Filing
Wijkstrom Joakim 4
Accession 0000950170-24-027259
CIK 0001347178other
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 4:48 PM ET
Size
7.3 KB
Accession
0000950170-24-027259
Insider Transaction Report
Form 4
Wijkstrom Joakim
SVP, Chief Marketing Officer
Transactions
- Sale
Common Stock
2024-03-05$4.21/sh−9,229$38,830→ 129,789 total - Sale
Common Stock
2024-03-04$4.41/sh−7,498$33,091→ 139,018 total
Footnotes (3)
- [F1]Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the default "same day sale" provisions of the RSU agreements.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.38 to $4.4402, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.2027 to $4.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Documents
Issuer
Vanda Pharmaceuticals Inc.
CIK 0001347178
Entity typeother
Related Parties
1- filerCIK 0001785888
Filing Metadata
- Form type
- 4
- Filed
- Mar 5, 7:00 PM ET
- Accepted
- Mar 6, 4:48 PM ET
- Size
- 7.3 KB